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RESEARCH ARTICLE
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d

The role of the complement system in HIV-1 immunity and pathogenesis is multifaceted, and an improved understanding of complement activities mediated by HIV-1-speciﬁc antibodies has the potential to inform and advance clinical development efforts. A seminal nonhuman primate challenge experiment suggested
that complement was dispensable for the protective effect of the early broadly neutralizing antibody (bnAb) b12, but recent experiments have raised questions about
the breadth of circumstances under which this conclusion may hold. Here, we reassess the original observation using Fc variants of IgG1 b12 that enhance complement activity and report that complement ﬁxation on recombinant antigen, virions,
and cells and complement-dependent viral and cellular lysis in vitro vary among
bnAbs. Speciﬁcally, while the clinically signiﬁcant V3 glycan-speciﬁc bnAb 10-1074
demonstrates activity, we found that b12 does not meaningfully activate the classical
complement cascade. Consistent with avid engagement by C1q and its complex system of regulatory factors, these results suggest that complement-mediated antibody
activities demonstrate a high degree of context dependence and motivate revisiting
the role of complement in antibody-mediated prevention of HIV-1 infection by nextgeneration bnAbs in new translational studies in animal models.
IMPORTANCE Given the suboptimal outcome of VRC01 antibody-mediated prevention
of HIV-1 infection in its ﬁrst ﬁeld trial, means to improve diverse antiviral activities in
vivo have renewed importance. This work revisits a loss-of-function experiment that
investigated the mechanism of action of b12, a similar antibody, and ﬁnds that the
reason why complement-mediated antiviral activities were not observed to contribute to protection may be the inherent lack of activity of wild-type b12, raising the
prospect that this mechanism may contribute in the context of other HIV-speciﬁc
antibodies.
KEYWORDS antibody, Fc, complement, CDC, viral lysis, C1q, antibody-mediated
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ecombinant antibodies represent a proven antiviral intervention (1), with U.S. FDA
approval of palivizumab (Synagis) for respiratory syncytial virus (RSV) prophylaxis
in infants and the antibody cocktail atoltivimab/maftivimab/odesivimab (Inmazeb) for
Ebola virus postexposure prophylaxis and FDA emergency use authorizations granted
for three antibody treatments for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection at the time of writing (2–4). In the absence of an effective vaccine, anti-human immunodeﬁciency virus type 1 (HIV-1) antibody discovery and clinical
development strategies have focused on those that potently neutralize virus via the
recognition of epitopes conserved across viral phylogenetic diversity (5). As of May
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2020, 28 such broadly neutralizing anti-HIV-1 antibodies (bnAbs) were the subject of
167 clinical trials, of which 32 trials of 9 bnAbs alone or in combination were investigating protection against infection in healthy, uninfected subjects (6).
The highly anticipated results of the ﬁrst of these studies to report on efﬁcacy, the
phase 2b Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN
703/HPTN 081), revealed the bnAb VRC01 to be protective against the acquisition of
VRC01 neutralization-sensitive HIV-1 strains (7). The results suggest that antibody prophylaxis is possible in humans, but the risk reduction is more modest than hoped, leaving open the potential of bioengineering strategies to optimize antibody-mediated
prevention.
The ability of some antibodies to oligomerize on antigenic surfaces (8) and activate
the complement cascade represents an arm of extraneutralizing functions that is well
studied and whose importance is well understood in the ﬁeld of immune oncology (9),
yet enthusiasm about its contribution to antibody-mediated protection against HIV-1
infection as a means of augmenting neutralizing antibody drugs was largely extinguished by a seminal nonhuman primate (NHP) passive immunization and challenge
experiment designed to determine antibody mechanism of action (10). In this inﬂuential study, a variant of the bnAb b12 with Fc domain mutations designed to eliminate
Fc receptor (FcgR) and complement initiator C1q binding (LALA) provided protection
diminished from that of the unmodiﬁed antibody, while a C1q-only knockout (KA) variant demonstrated protection equivalent to that of unmodiﬁed b12, suggesting that
FcgR- but not complement-mediated functions contributed to protection from infection in vivo (10). In contrast, two similar experiments conducted with a more potent
bnAb, PGT121, reported no difference in resistance to infection when this antibody
was modiﬁed to eliminate both FcgR and complement activities (11, 12). Analysis of
how the passive transfer of other bnAb-based interventions in the context of established infection has further supported the role of effector functions with in vivo antiviral activity (13) but has not deﬁned the role that the complement cascade might play.
Here, we revisit the biological activity of the b12 antibody in vitro in an effort to
more fully examine the interpretation of the original NHP challenge experiment in the
context of ongoing clinical evaluation of antibody-based prophylaxes. Our ﬁndings
suggest that the conclusion of Hessell et al. (10), that complement does not contribute
to b12 activity in vivo, is clear and well supported; however, reconsideration of classical
complement activity as a factor in either protection or enhanced pathogenesis is warranted for other bnAbs in development. In either scenario, an advanced understanding
of the interplay between classical complement and HIV-1 can be productively incorporated into future antibody-mediated prevention strategies.
RESULTS
Characterization of a panel of b12 variants. A panel of b12 Fc variants, including
those used in the NHP challenge experiment, was designed to assess various in vitro
measures of complement-dependent antibody activity. The panel consisted of two variants, KA and EG, that are known to possess a selectively modiﬁed C1q binding phenotype, and two variants, LALA and EFTAE, that exhibit an altered interaction proﬁle with
C1q and across FcgRs (Fig. 1A). The binding knockout variants KA and LALA (14, 15) as
well as two enhancing variants, EG (16) and EFTAE (17, 18), were cloned, expressed,
and characterized for conformance to literature phenotypes. These antibodies exhibited essentially identical binding afﬁnities for YU-2 gp140 trimers as assessed by biolayer interferometry (BLI) (Fig. 1B) but showed marked differences in their abilities to
interact with human FcgRs, as assessed using a customized multiplex assay (Fig. 1C). As
others have reported (19), the LALA variant retained moderate binding to tetramerized
FcgRIIIA despite being originally characterized as a pan-FcgR knockout (15). Both the
complement-enhancing EG variant and the complement knockout KA variant exhibited comparable proﬁles of FcgR binding to unmodiﬁed b12, whereas the dual-complement and FcgR-binding-enhanced EFTAE variant showed elevated binding to FcgR.
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FIG 1 b12 variant panel. (A) Antibody (Ab) IgG1 Fc variants illustrated on the crystal structure of the broadly neutralizing antibody b12 (PDB accession
number 1HZH) by coloration of the component point mutations. The phenotypically diminished variants to the left of b12 are illustrated in red (e.g., LALA
and KA), while phenotypically enhanced variants to the right are in blue (e.g., EG and EFTAE). Accompanying the illustrations is a table of expected
qualitative C1q and FcgR binding phenotypes and observed afﬁnity of antigen binding (equilibrium [kinetic] dissociation constant [KD] values) of each
variant to antigen (HIV-1YU-2 gp140 trimer). (B) Antigen binding proﬁles determined by biolayer interferometry (BLI) across a range of concentrations. (C)
FcgR binding proﬁles of each variant as determined by staining antigen-conjugated beads with tetramerized receptor. Error bars represent the ranges from
two technical replicates.

To assess the inherent ability of each variant to engage C1 and ﬁx complement,
enzyme-linked immunosorbent assays (ELISAs) were performed using antibody-coated
microtiter plate wells as described previously by Hessell et al. (10) (Fig. 2A). Variants
LALA and KA showed ablated C1q binding relative to unmodiﬁed b12 and the isotype
control VRC01 (Fig. 2A, left). Elevated C1q binding was observed for both the EFTAE
and EG variants, which directly or indirectly improve the interaction of Fc with hexavalent C1q via improved C1q binding afﬁnity or increased oligomerization potential,
respectively. Detection of C3d was used as a measure of total C3 ﬁxation as it is detectable regardless of postdeposition proteolytic processing. Deposition of C3d was undetectable for KA and dramatically reduced by the LALA mutations (Fig. 2A, right).
Despite the greater C1q binding with the EG and EFTAE variants than that mediated
by unmodiﬁed b12, unmodiﬁed and enhanced variants displayed equivalent levels of
C3d deposition. Additionally, a moderate level of C3d deposition was retained by the
LALA variant despite undetectable C1q binding.
Complement activation is context dependent. Structural studies have shown that
C1q engagement depends heavily on the quaternary organization of adjacent antibody Fc domains (8, 20), which in turn can be inﬂuenced by the local concentration
September/October 2021 Volume 12 Issue 5 e01743-21
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FIG 2 The ability of b12 to activate complement is inﬂuenced by assay setup and antigen context. (A) The antigen-independent
ability of the antibody panel to bind C1q (left) and ﬁx complement (right) was determined by ELISAs via antibody-coated wells.
(B and C) Beads conjugated with SHIVSF162P3 gp120 (B) or HIV-1YU-2 gp140 trimer (C) were used to assay antigen binding (left),
C1q binding (center), and complement fragment C3d deposition (right). Antigen beads treated with PNGase F were used to
assess the impact of N-linked antigen glycosylation antibody-independent activation and to isolate antibody-dependent C3d
deposition (shaded). For C3d deposition on non-PNGase F-treated antigen beads, background activity is reported as the average
MFI (dotted line) 6 standard deviation (shaded region on the y axis) of anti-C3d detected on beads in replicate wells of pooled
NHS (n = 6) in the absence of antibody. Data are representative of results from two independent experiments. AU, arbitrary units.

and orientation of antigen (21). Therefore, we sought to reevaluate C1q recruitment
and C3d deposition within the context of antigen-antibody complexes.
Brieﬂy, antibodies were ﬁrst incubated with antigen-coupled microspheres before
being assessed for C1q recruitment and C3d deposition. All Fc variants of b12 displayed similar levels of binding to the simian-human immunodeﬁciency virus
SHIVSF162P3 gp120 monomer (Fig. 2B, left) and the HIV-1YU-2 gp140 trimer (Fig. 2C, left).
In contrast to the ELISA results, however, unmodiﬁed b12 failed to recruit human C1q
in the antigen-dependent assay (Fig. 2B and C, center). Only the EFTAE variant exhibited robust, concentration-dependent C1q engagement with both gp120 and gp140
antigens (Fig. 2B and C, center). In contrast, b12 EG complexed with the gp140 trimer
(Fig. 2C, center) mediated detectable C1q recruitment but failed to do so in complex
with the gp120 monomer (Fig. 2B, center). Antibody-dependent C3d deposition was
not observed with SHIVSF162P3 gp120 (Fig. 2B, right) as activity was obscured by an elevated baseline level of complement ﬁxation. Since antibody-dependent activity was
resolved following treatment of antigen beads with peptide-N-glycosidase F (PNGase
F) (Fig. 2B, shaded), the elevated background deposition can be attributed to lectin
and alternative pathway activation by direct interaction with antigen glycosylation. In
September/October 2021 Volume 12 Issue 5 e01743-21
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contrast, EFTAE and EG drove elevated C3d deposition when bound to the HIV-1YU-2
gp140 trimer, while those that did not recruit C1q, such as IgG1 b12, appeared to inhibit non-antibody-mediated activation pathways (Fig. 2C, right). Again, antibody-dependent differences in activation were further resolved using PNGase F-treated beads
(Fig. 2C, shaded).
Complement is activated by a clinically relevant anti-HIV-1 bnAb. Multiple antiHIV-1 bnAbs are currently being evaluated as agents of preexposure prophylaxis. In
order to assess whether anti-HIV-1 antibodies undergoing clinical development are capable of driving complement activation and ﬁxation, a small panel consisting of bnAbs
(and a nonneutralizing monoclonal antibody [mAb]) targeting two distinct epitope
regions was generated and evaluated for the ability to drive the deposition of C3 on
Env-conjugated beads (Fig. 3). The panel consisted of the CD4 binding site (CD4bs)speciﬁc bnAbs b12 and VRC01, the nonneutralizing anti-HIV-1 antibody b6, as well as
the V3-loop-associated N332 glycan patch-speciﬁc bnAbs PGT121 and 10-1074.
Additionally, Fc variants of these antibodies were produced to potentiate and knock
out complement activation, with the goal of revealing antibody-speciﬁc differences.
The Fc variants that were evaluated consisted of EFTAE, LALA, as well as the additional
enhancing variants Y300D (20) and E345R (8, 16).
To begin to compare activities in human and rhesus macaques, the activity of
pooled human serum with and without heat inactivation was compared to the activity
observed in the presence of serum from two individual macaques. While higher levels
of C3d deposition were generally observed for the macaque serum samples, variation
between individuals appeared to be comparable to variation between species (Fig. 3).
Signiﬁcantly, trends between antibodies and Fc variants were consistent across different complement sources.
Of the unmodiﬁed anti-HIV-1 mAbs tested, only 10-1074 displayed detectable C3d
deposition in each of the three sources of complement-preserved serum tested, and in
each of the Fc-enhanced forms, 10-1074 displayed a nearly equivalently high anti-C3d
signal (Fig. 3). The bnAb b12 drove ﬁxation only in the EFTAE Fc format; however, the
signal was moderate to low compared to those of the other EFTAE-modiﬁed mAbs
tested. Interestingly, the point mutation E345R but not Y300D potentiated complement activation by VRC01. Such an observation might be attributable to antibodySeptember/October 2021 Volume 12 Issue 5 e01743-21
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FIG 3 Complement is activated by the clinically investigated anti-HIV-1 bnAb 10-1074. The degree to which a
panel of anti-HIV-1 antibodies ﬁxes complement (C3d) on the surface of HIV-1SF162 gp140 trimer-conjugated
beads was evaluated using both the complement-preserved serum of individual monkey donors (n = 2) as well
as complement-active and heat-inactivated pooled human serum. The leftmost panel compares the activities
elicited by antibodies with unmodiﬁed Fc domains, while the box to the right displays the same panel of
antibodies, or a subset thereof, grouped by Fc variant identity, with color-coded points indicating the antibody
speciﬁcity (black and blue indicate the CD4bs, and shades of green indicate the V3-glycan patch; light and dark
shades indicate lower to higher relative neutralization potencies, respectively). Points and error bars represent
the means and ranges from two technical replicates, respectively, with the shape indicating the source of
complement assayed. Background ﬁxation, reported as the average MFI of anti-C3d detected in replicate wells
of pooled NHS in the absence of antibody, is indicated by a dotted line, with the range denoted by the shaded
region on the y axis.

®

FIG 4 Complement-enhanced Fc variants of IgG1 b12 do not mediate viral lysis despite detectable deposition activity on
viral particles. Antibodies were assayed for their ability to bind to the surface of HIV-1BaL particles bound to lectinconjugated magnetic beads (A), recruit C1q to the viral surface (B), and affect terminal complement activities, including
C3 deposition (C), C5b-9 complex formation (D), and MAC-mediated lysis (E), determined by the detection of released
capsid protein p24. Dotted lines represent average baseline complement deposition on beads in wells containing a
nonspeciﬁc isotype control (A to D) or antibody-independent baseline complement deposition and heat-inactivated NHS
(E). Points and error bars represent means 6 standard deviations from technical triplicates, respectively. Data are reported
as mean or median ﬂuorescence intensities (mFI or MFI, respectively) and are representative of results from two
independent experiments. huIgG, human IgG.

speciﬁc differences in complement biology; the integration of these mutations with
differences in the approach angle, orientation, or ﬂexibility of the Fc ultimately may
impact the propensity for Fc-Fc oligomerization and Fc-C1q association. Of note, the
EFTAE variant uniformly potentiated complement activation across the bnAbs and
nonneutralizing mAb tested, which is consistent with the proposed mechanism of
directly increasing the afﬁnity of the collagenous heads of C1q for IgG Fc.
Increasing biological complexity modulates antibody-dependent complement
activation. In the context of viral transmission, both virus and envelope on the surface
of infected cells represent important targets of antibody-mediated prevention strategies. In order to approximate the behavior of b12 in more biologically relevant contexts and enable the evaluation of terminal complement activation, virus (Fig. 4) and
envelope-expressing cells (Fig. 5) were used as target particles.
To evaluate antibody-driven complement activity against virus, lectin-conjugated
beads were used to capture HIV-1BaL virions and subsequently incubated with antibody
and a source of complement. Antibody binding to lectin-bead-captured HIV-1BaL
(Fig. 4A) and the subsequent recruitment of C1q (Fig. 4B) revealed concentration-dependent virus binding for the antibodies tested and detectable recruitment of C1q by
only the EFTAE Fc variant of b12, respectively. The complement cascade intermediate
C3 (Fig. 4C) and C5b-9 (Fig. 4D), a precursor of membrane attack complex (MAC)-mediated lysis, were detected on lectin-conjugated-bead-captured HIV-1BaL virions. Despite
the limited detection of C1q, EFTAE and, to a lesser extent, EG were observed to drive
both C3b deposition and C5b-9 membrane insertion, while unmodiﬁed IgG1 b12 displayed signiﬁcantly weaker activity, and knockout variants reported signals equivalent
September/October 2021 Volume 12 Issue 5 e01743-21
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FIG 5 IgG1 b12 does not measurably direct complement activity against Env-expressing cells, while the CDC activity of
enhanced Fc variants depends on the target cell. Antibodies were assayed for their abilities to bind to the surface of HIV-1JR-FL
gp140 transiently expressed on HEK293F cells (A), recruit C1q to HEKJR-FL cells (B), and affect terminal complement activities
targeting the antibody-opsonized HEKJR-FL cell surface, including C3 deposition (C), C5b-9 complex formation (D), and MACmediated lysis of two distinct Env-expressing cell models (E). Dotted lines represent average baseline complement deposition
on cells in wells lacking antibody (A to D). Points and error bars represent means from technical triplicates (A to D and E, top)
or from three serum donors (E, bottom) and standard deviations, respectively. Data are representative of results from at least
two independent experiments.

to that of an isotype control. In contrast, virion lysis, as measured by the release of
capsid protein p24, was not appreciably observed above background levels for any
of the b12 variants tested, although antibody concentration-dependent complement-mediated lysis was observed with the EFTAE variant of the MPER-speciﬁc bnAb
10E8v4 (Fig. 4E).
To evaluate antibody-driven complement activity against cell-associated virus,
HEK293F cells transiently expressing HIV-1JR-FL gp140 (HEKJR-FL cells) were incubated
with antibody and a source of complement. While antibody binding to HEKJR-FL cells
revealed equivalent antigen binding (Fig. 5A), only the EFTAE Fc variant of b12 and, to
a lesser extent, EG displayed detectable recruitment of C1q (Fig. 5B). In agreement
with C1q binding, only the EFTAE and EG Fc variants of b12 promoted C3b deposition
(Fig. 5C) and C5b-9 formation (Fig. 5D) on the surface of HEKJR-FL cells, while unmodiﬁed forms of b12 and another CD4bs-speciﬁc antibody, VRC01, displayed a signal indistinguishable from those of complement knockout variants of b12 and control wells
without antibody. In the HEKJR-FL cell model, enhanced variants of b12 and VRC01 were
observed to drive antibody-dependent complement-mediated cellular cytotoxicity,
while unmodiﬁed and knockout versions appeared to protect cells from antibody-independent complement pathways (Fig. 5E, top). While enhanced b12 variants were
shown to drive C3b deposition (Fig. 5C), C5b-9 complex formation (Fig. 5D), and complement-dependent cytotoxicity (CDC) (Fig. 5E, top) in the context of HEK cells transiently expressing HIV-1JR-FL gp140, b12 in all formats tested failed to induce CDC of Raji
cells stably expressing either intermediate or high levels of surface envelope (Fig. 5E,
bottom). This deﬁciency was speciﬁc to b12, as CDC was robustly elicited by both
unmodiﬁed and EFTAE forms of VRC01.
September/October 2021 Volume 12 Issue 5 e01743-21
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DISCUSSION
Collectively, these data suggest that while unmodiﬁed and Fc variant forms of b12
exhibit the intrinsic biophysical interaction proﬁle expected of them, they inherently
lack the capacity to drive complement activity when biologically signiﬁcant factors are
incorporated into in vitro assays. Between intrinsic activity and that observed in the
context of recombinant antigen, viral particles, and envelope-expressing cells used to
model infected cells, we repeatedly observed differences in C1q binding, C3 deposition, C5b-9 formation, and lytic activity. Similarly, the identity (strain) and composition
(monomer or trimer) (glycosylation state) of target antigens inﬂuenced diverse antibody-mediated complement phenotypes, and distinguishing antibody-mediated from
antibody-independent complement activation was strongly dependent on the concentration of the complement source (data not shown). While these observations suggest
that making predictions of in vivo activity from in vitro data appears not to be straightforward, the lack of activity observed for unmodiﬁed b12 across a variety of assay formats makes it clear that reinterpretation of the classic mechanism-of-action experiment is warranted. Importantly, this loss-of-function antibody infusion experiment
deﬁnitively established a protective contribution of Fc receptor-mediated functions.
However, because unmodiﬁed b12 appears not to exhibit meaningful complement-dependent activity in these and similar cell-based assays (22), its evaluation in vivo to
inform on the contribution of complement to antibody-mediated prevention of infection appears to be limited.
Early studies implicated complement activation in HIV-1 infection enhancement
(23–29). More recently, it has been reported that complement-opsonized virus promotes viral establishment in colorectal mucosa (30) and infection of mucosa-resident
Langerhans cells (31). Evidence suggests that complement opsonization makes HIV-1
more accessible to host cells via interactions with complement receptors. In addition
to mediating cellular adherence, complement-opsonized HIV was shown to be more
efﬁciently internalized by (32) and overcome restriction in (33) dendritic cells (DCs).
Downstream implications have been demonstrated to include interference with immature DC signaling pathways, resulting in decreased inﬂammatory and antiviral responses
(34, 35) and reduced cytolytic potential of NK (34, 36) and CD8 T (30, 36) cells.
Opsonization has also been hypothesized to contribute to viral reservoir maintenance in
germinal centers via interaction with follicular dendritic cell-associated complement receptor 2 (CR2) (37). In line with this observation, hypofunctional CR2 polymorphisms have
been shown to correlate with innate resistance to HIV-1 infection (38), and an association
has been found between a single-nucleotide polymorphism (SNP) in the CR2 gene and
susceptibility to infection among gp120-vaccinated individuals in a low-risk category (39).
While evidence suggests that upstream complement opsonins contribute to complement-enhanced infectivity, both HIV-1 virions and infected cells possess mechanisms for evading downstream complement-mediated lysis. Budding virions incorporate host membrane CD59 that inhibits complement fragment C9 polymerization and
September/October 2021 Volume 12 Issue 5 e01743-21
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In summary, measures of sublytic complement activity detected on target virions
(Fig. 3D and Fig. 4C) and envelope-expressing cells (Fig. 4D and Fig. 5C) mostly agreed
with those detected on Env trimer-conjugated beads (Fig. 2C), at least in comparative
antibody rank-order activity or activity interpreted as a binary variable. Distinctions
between the detection of C1q recruitment (Fig. 4B) and complement deposition
(Fig. 3D and Fig. 4C) were noted for unmodiﬁed and EG forms of b12. Importantly,
unmodiﬁed b12 did not measurably direct lytic complement activity against either virus (Fig. 4E) or envelope-expressing target cells (Fig. 5E), although CDC mediated by
complement-enhanced Fc variants highlights the differences that can exist between
target cell models. Overall, these results demonstrate the degree of comparability
between various measures of complement activity across several in vitro models and
speciﬁcally indicate that IgG1 b12 is not an active driver of classical complement
activation.
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lytic pore formation (40). When this glycophosphatidylinositol (GPI)-anchored glycoprotein was blocked, complement-mediated viral and infected cell lysis was restored
(41). However, the impact of CD59 on simian immunodeﬁciency virus (SIV) complement evasion was shown to be nearly negligible in experiments in which CD59 was
cleaved from virion membranes with phosphoinositide phospholipase C (42). In
addition to CD59 and other complement-restricting host factors (40, 43), the viral
accessory proteins Vpu and Nef have been implicated in restricting membrane
attack complex (MAC)-mediated lysis of infected primary CD41 T cells by modulating
surface Env levels (22).
Despite potential indications of complement-enhanced infection and the knowledge that pathogen and host factors facilitate HIV-1 complement evasion, studies that
offer counterevidence exist, suggesting a possible antiviral role for antibody-driven
complement activation. For example, plasma HIV-1 was shown to be susceptible to
complement-mediated lysis (44), and plasma from both chronically and acutely
infected patients triggered viral inactivation (45) and lysis (46) against an autologous
virus isolate, with lytic activity being correlated with lower viral loads (46). These studies suggest that antibody-mediated complement-dependent virion lysis develops early
in the course of infection and may reduce viremia in vivo. Also, lytic activity is not the
only means by which complement may function. For example, an early study suggested that complement can neutralize plasma virus by a C5-independent mechanism
(47), suggesting a possible mechanism of upstream complement component opsonization-mediated inactivation of HIV-1. A parallel observation has been made for another
enveloped virus, human cytomegalovirus (HCMV), for which complement opsonization
was demonstrated to enhance the in vitro neutralizing potency of monoclonal antibodies and immune sera (48). Furthermore, complement fragment opsonization may assist
in the promotion of viremia-controlling adaptive responses (49–51).
Conﬂicting evidence for the role of antibody-mediated complement in the prevention
or pathophysiology of HIV-1 may be explainable as being highly dependent on contextual variables such as HIV and host diversity as well as antibody-intrinsic factors. For example, in an early V3-speciﬁc antibody-mediated postexposure protection mouse study, artiﬁcially depleting the serum complement by treatment with cobra venom factor (CVF)
was shown to abrogate the antibody’s protective capacity (52), with the caveat that while
CVF treatment consumes nearly 100% of serum C3, large quantities of proinﬂammatory
C3a and C5a, among other by-products, are generated in the process and represent a
nontrivial systemic source of confounding factors. Also, V1V2-speciﬁc complement-activating serum IgG was deﬁned as a correlate of reduced HIV-1 infection risk in the RV144
vaccine trial that demonstrated moderate protective efﬁcacy (53).
Previous in vitro characterizations of monoclonal antibodies generated similar
observations, that complement activities vary across distinct epitopes (54, 55), dependent on ﬁne details of the geometry of antibody interactions with antigen (56, 57), C1q
(8, 18, 58, 59), and self (oligomerization propensity) (8, 16). The collective result is that
the activity observed in in vitro assays appears to be exquisitely sensitive to design
details, challenging abstraction to expected effects in vivo. As examples, we and others
have observed considerable differences between early (C3 deposition) and late (lytic)
activities, between target cells or viruses, and in the context of antigen/virus diversity
(22). Additionally, testing in nonhuman primates, and speciﬁcally in rhesus macaques,
may introduce confounders to clinical translation related to as-yet-undiscovered
cross-species differences in upstream factors inﬂuencing complement regulation or
downstream processes like immune complex shuttling and processing or in relation
to differences between HIV and SHIV. While interspecies differences may exist in the
composition or the mechanistic or regulatory nuances of notably complex complement biochemistry, preliminary assessments comparing complement-preserved
human and rhesus macaque sera resulted in relatively consistent levels of deposition
on antibody-opsonized recombinant antigen beads. Moreover, the bnAb Fc variants
maintained rank-order deposition signals independent of the species source of
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complement. While unresolved interspecies differences and well-established limitations of in vitro assessments constrain the scope of our ﬁndings, the data presented
here call into question the perhaps widely held notion that complement is unimportant in antibody-mediated protection against HIV.
Given the suboptimal efﬁcacy of antibody-mediated prevention of HIV-1 infection
in its ﬁrst ﬁeld trial (7), means to improve diverse antiviral activities in vivo have
renewed importance, and while b12 has been shown to lack the capacity to activate
complement, we and others have observed that the V3-glycan patch-speciﬁc bnAb 101074 drives C3 deposition on Env-conjugated beads and Raji cells expressing Env (22),
and the MPER-speciﬁc bnAb 10E8v4 drives lysis of HIV-1BaL virions (D. A. Spencer, B. S.
Goldberg, J. Duﬂoo, T. Bruel, S. Pandey, T. Cheever, P. Barnette, W. F. Sutton, H.
Henderson, R. Agnor, L. Gao, O. Schwartz, N. L. Haigwood, M. E. Ackerman, and A. J.
Hessell, unpublished data). Importantly, 10-1074 has been shown to suppress viremia
in infected individuals (60) and, like several other bnAbs, is under clinical evaluation
(ClinicalTrials.gov identiﬁer NCT03554408) at the time of writing. While much remains
unresolved regarding a comprehensive understanding of the role of complementmediated activity in the antibody-based prevention or treatment of HIV-1 infection,
the potential importance of either direct lytic functions or other antiviral or adjuvantlike activities should not be overlooked without further investigation. Indeed, complement-dependent lysis has been established as an important mechanism of action of
the ﬁrst monoclonal antibody therapeutic approved for the treatment of cancer, rituximab (61), which, unlike anti-CD20 antibodies targeting other epitopes (56), activates
complement so strongly that it depletes serum complement during infusion (62).
While our study and other studies of HIV-1 bnAbs in animal models suggest that the
ability to use in vitro results to guide in vivo translation may be challenging, complement activity may yet prove to be a useful means to drive viral lysis and act in concert
with direct neutralization and other effector functions or may alternatively play a role
in pathogenesis. To this end, engineered antibody variants represent an important tool
to understand the complex interplay among drug, host, and pathogen in vivo and
thereby offer new means to improve upon our ability to prevent and treat HIV-1
infection.
MATERIALS AND METHODS
Generation of antibody Fc variants and recombinant antigens. Plasmids for the soluble expression of the HIV-1YU-2 gp140 trimer (catalog number ARP-12133) and VRC01 heavy chain (catalog number
ARP-12035) and light chain (catalog number ARP-12036) IgG1 were obtained through the NIH AIDS
Reagent Program. DNA for b12 heavy and light chain sequences originate from Zwick et al. (63), DNA for
b6 sequences originate from Roben et al. (64), and nucleotide sequences for PGT121 and 10-1074 were
provided by Hugo Mouquet and Marina Caskey, and the cloning of these sequences was ﬁrst reported
in Mouquet et al. (65). Fc domain variants (EFTAE, EG, KA, LALA, Y300D, and E345R) of each antibody
were cloned via site-directed mutagenesis using the QuikChange II site-directed mutagenesis kit (catalog number 200523; Agilent Technologies) according to the manufacturer’s directions. The desired incorporation of Fc substitutions was conﬁrmed by Sanger sequencing (Genewiz).
Antibodies were produced using the Expi293 expression system. Brieﬂy, heavy and light chain plasmids were transiently cotransfected into Expi293F cells (catalog number A14635; Thermo Fisher) according to the ExpiFectamine 293 transfection kit (catalog number A14525; Thermo Fisher) protocol. Culture
supernatants were collected at 7 days posttransfection, puriﬁed by gravity using MabSelect protein A
chromatography resin (catalog number 17519903; GE Healthcare), and polished via size exclusion chromatography (SEC) on a Superdex 200 column (catalog number 28989335; GE Healthcare).
The recombinant HIV-1YU-2 gp140 trimer was produced by transient transfection in HEK293F cells
using polyethyleneimine (PEI) (catalog number 23966; Polysciences). Cell supernatants were harvested
after 5 to 7 days, and clariﬁed supernatants were puriﬁed by ion metal afﬁnity chromatography with a
HisTrap Excel column (catalog number 17-3712-06; GE Healthcare) on an Äkta pure chromatography system (GE Healthcare). Puriﬁed gp140 was polished via SEC on a Superdex 200 column (catalog number
28989335; GE Healthcare).
Kinetics analysis of antibody binding to HIV-1 gp140 via biolayer interferometry. The binding
of unmodiﬁed b12 and Fc variants (KA, LALA, EG, and EFTAE) to the HIV-1YU-2 gp140 trimer was evaluated via BLI using the Octet RED96 instrument (Sartorius AG). Samples and controls were formulated in
1 kinetics buffer (1 phosphate-buffered saline [PBS], 0.1% bovine serum albumin [BSA], 0.02% Tween
20) and added to black 96-well F-bottom polypropylene microplates (catalog number 655209; Greiner
Bio-One). High-precision streptavidin biosensors (catalog number 18-5117; Sartorius AG) were activated
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by soaking for 10 min in wells containing 5 m g/ml biotinylated anti-His tag antibody (catalog number
4603-08; Southern Biotech), followed by loading of the HIV-1YU-2 gp140 trimer (His tagged) to a threshold
RU (response units) of 0.3 nm. After 60 s at baseline in 1 kinetics buffer, gp140-loaded biosensors were
dipped into serially diluted IgG (0.171 to 125 nM) to measure association for 300 s, followed by dissociation for 300 s in kinetics buffer. A reference biosensor dipped into a well containing kinetics buffer was
used to subtract nonspeciﬁc signal. Biosensors were regenerated to the anti-His tag antibody between
fresh antigen loading and subsequent sample association and dissociation steps using regeneration
buffer (10 mM glycine, pH 1.7). Kinetic constants were determined by ﬁtting traces to a 1:1 binding isotherm by FortéBio HT analysis software (version 11.1.1.39).
Antibody and Fc receptor binding in a microsphere-based immunoassay. HIV-1YU-2 gp140 trimer
and SHIVSF162P3 gp120 (catalog number IT-001-146p; Immune Technology Corp.) antigens were covalently coupled to coded MagPlex superparamagnetic carboxylated magnetic microparticles (Luminex
Corp.) using carbodiimide cross-linking chemistry as previously described (66). To evaluate antibody
binding by unmodiﬁed IgG and Fc variants, gp140- and gp120-coupled beads were incubated in a multiplex format with IgG for 1 h at room temperature (RT) with shaking. Plates were washed ﬁve times on an
automated plate washer (catalog number 405; BioTek) and subsequently detected with 0.7 m g/ml phycoerythrin (PE)-conjugated goat anti-human IgG Fc (catalog number 2048-09; Southern Biotech) for 1 h
at RT with shaking. Following ﬁve washes, beads were resuspended in xMAP sheath ﬂuid (Luminex
Corp.), and sample median ﬂuorescence intensities (MFIs) were collected using the Magpix system
(Luminex Corp.).
Human Fc receptor binding proﬁles were generated by a custom multiplex assay as previously
described (66). Brieﬂy, SHIVSF162P3 gp140-coupled beads were incubated with serial dilutions (50 pM to
500 nM) of IgG for 1 h at RT and washed ﬁve times using an automated plate washer. FcgR tetramers
were prepared by incubating the biotinylated soluble human Fc receptors FcgRIIA, FcgRIIB, FcgRIIIA, and
FcgRIIIB (generously provided by Shelly Krebs, U.S. Military HIV Research Program) with streptavidin-PE
(catalog number PJRS25; Prozyme) in a 4:1 molar ratio for 20 min at RT. Detection reagent tetramers
were incubated with antibody-antigen-bead complexes at 1.0 m g/ml for 1 h at RT with constant agitation. The excess tetramerized receptor was removed by ﬁve washes prior to ﬂow cytometric analysis on
the Flexmap 3D system (Luminex Corp.). Data are reported as the averages and ranges from two technical replicates. The background signal as a result of nonspeciﬁc interactions was minimal and not
subtracted.
Antigen-free C1q binding and C3d deposition determined by ELISAs. Antibody-mediated complement activity was assessed in an antigen-independent manner through colorimetric ELISA-based
measurements of C1q binding and C3d deposition. Antibodies were serially diluted 2-fold (0.13 to
66.67 nM) in coating buffer (50 mM carbonate-bicarbonate, pH 9.6) and immobilized to clear high-protein-binding-capacity 96-well ELISA plates (catalog number 423501; BioLegend) overnight at 4°C. Plates
were subsequently washed three times with PBS-T (1 PBS, 0.05% [vol/vol] Tween 20) prior to blocking
with 2% BSA for 2 h at RT.
For the detection of C1q binding, antibody-coated wells were incubated with 1 m g/ml biotinylated
human C1q for 1 h at RT. Unbound C1q was removed by washing, and plates were subsequently incubated with a 1:200 dilution of horseradish peroxidase (HRP)-conjugated streptavidin (catalog number
890803; R&D Systems) for 20 min at RT. Next, plates were washed and developed with a TMB (3,39,5,59tetramethylbenzidine) substrate solution (catalog number N301; Thermo Scientiﬁc) according to the
manufacturer’s instructions. Human C1q (catalog number ab96363; Abcam) was biotinylated by primary
amine coupling using EZ-Link sulfo-NHS (N-hydroxysuccinimide)-biotin (catalog number A39256;
Thermo Scientiﬁc) according to the manufacturer’s instructions.
For the detection of C3d deposition, IgG-coated plates were incubated with normal human serum
(NHS) (catalog number S174; Sigma-Aldrich) or heat-inactivated NHS (HI-NHS) ($30 min at 56°C) diluted
1:100 in gelatin veronal buffer supplemented with Ca21 and Mg21 (GVB11) (catalog number G6514;
Sigma-Aldrich) for 30 min at 37°C, placed on ice to halt the complement activation reaction, and washed
three times with PBS-T. Next, a 1:1,000 dilution of biotinylated anti-human C3d (catalog number A702;
Quidel) in PBS-T was added for 1 h at RT. After three washes, plates were incubated with streptavidinHRP followed by detection with the TMB substrate as described above. Reactions were stopped with
0.16 M sulfuric acid, and absorbances were read at 450 nm on a SpectraMax Paradigm multimode UVspec microplate reader (Molecular Devices). Wells that did not contain immobilized antibody served as
background controls. Data shown are averages from two technical replicates and are representative of
results from two independent experiments.
C1q binding and C3d deposition using antigen-coated microspheres. Antigen-coupled microspheres were prepared as described above and incubated in a multiplex format with IgG 3-fold serially
diluted (5 pM to 300 nM) in assay buffer (1 PBS, 0.1% BSA, 0.05% Tween 20) for 1 h at RT. Following
the removal of excess IgG with ﬁve washes in assay buffer, antibody-antigen complexes were assessed
for their ability to recruit C1q and drive classical complement activation, as follows.
Assessment of C1q binding was carried out as previously described (66). Brieﬂy, 1 m g/ml biotinylated
human C1q was incubated for 1 h at RT, followed by washing and incubation with a 1:500 dilution of
streptavidin-PE (catalog number PJRS25; Prozyme) for 30 min at RT. Beads were washed and resuspended in xMAP sheath ﬂuid (Luminex Corp.) before acquisition on the Magpix system (Luminex Corp.).
For C3d deposition assays, NHS (catalog number S174; Sigma-Aldrich) diluted 1:100 in GVB11 was
incubated with antibody-complexed antigen beads for 30 min at 37°C, placed on ice to stop complement activation reactions, washed, and incubated with 0.1 m g/ml biotinylated anti-human C3d (catalog
number A702; Quidel) for 1 h at RT with shaking. Following washes, bound anti-C3d antibodies were
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detected by incubation with 1 m g/ml streptavidin-PE (catalog number PJRS25; Prozyme) for 20 min at
RT, washed, and analyzed on the xMAP system (Luminex Corp.). For the experiment comparing the small
panel of anti-HIV-1 antibodies, antibodies were assayed at 100 nM. Complement-preserved individual
monkey serum was provided by the Oregon National Primate Research Center at Oregon Health &
Science University, and NHS was sourced from a distinct vendor (catalog number A112; Quidel). To
assess the impact of viral antigen N-linked glycosylation on antibody-independent activation, antigen
beads were treated with PNGase F (catalog number P0704S; New England BioLabs) under nondenaturing conditions according to the manufacturer’s protocol. Brieﬂy, antigen beads were mixed with
GlycoBuffer 2 (10), deionized water to a total volume of 20 m l, and PNGase F amidase; incubated at
37°C for 20 h; washed three times with PBS-TBN (TBN is 0.05% Tween 20, 1.0% BSA, 0.1% NaN3 [sodium
azide]) (catalog number P0210; Teknova); resuspended in GVB11; and used immediately in the C3d deposition assay as described above.
The data shown are representative of results from at least two independent experiments. Assay wells
containing assay buffer in lieu of antibody were used to assess background C1q association or complement activation driven by antibody-independent pathways. To control for nonspeciﬁc antibody-mediated activity, the anti-HIV-1 gp41 mAb 10E8v4 was used as a negative control in the gp120-conjugated
bead experiments.
Bead capture of viral particles. To generate bead-captured HIV virions, aldrithiol (AT-2)-treated
HIV-1BaL (generously provided by Jeffrey Lifson, National Cancer Institute) was captured by lectin-coated
beads via binding to glycan motifs on the viral surface. To prepare lectin-coated beads, 0.2 mg streptavidin Dynabeads (catalog number 11205D; Thermo Fisher Scientiﬁc) were washed ﬁve times with PBS and
resuspended in 200 m l of biotinylated Galanthus nivalis lectin (catalog number B-1245-2; Vector
Laboratories) diluted to a concentration of 0.1 mg/ml in PBS. The bead-lectin mixture was incubated for
20 min at RT with end-over-end rotation, followed by ﬁve PBS washes. Subsequently, 2 m g p24 of AT-2treated HIV-1BaL was incubated with 40 m g of lectin-coated beads for 90 min at RT with end-over-end
mixing, washed three times using a magnet, and resuspended in PBS-BSA (1 PBS, 0.1% [wt/vol] BSA)
for storage at 4°C.
The functional capture of virions and their ability to interact with anti-HIV-1 antibodies were tested
by incubation with titrating amounts of anti-HIV-1 antibodies, followed by secondary staining with PEconjugated goat anti-human IgG (catalog number 2040-09; Southern Biotech). After conﬁrmation of homogeneous capture, bead-captured virus was subsequently used for C1q binding and complement deposition experiments. While the capture of glycosylated viral debris, including free, degraded, or monomeric components of Env, cannot be precluded from inﬂuencing the detection of C1q association and
C3 deposition, the detection of C5b-9 can be viewed as validating viral capture as the stable insertion
and polymerization of C6-9 require an intact lipid bilayer. To help ensure the structural integrity of viral
particles, bead-captured virions were prepared fresh prior to each experiment.
C1q binding, C3 deposition, and C5b-9 formation on bead-captured HIV virions. To assess the
ability of antibody-opsonized cell-free HIV to recruit C1q and drive complement activation, bead-captured virus was incubated with serially diluted IgG in GVB11 for 20 min at 37°C with gentle shaking.
Concurrently, 1:10-diluted NHS in GVB11 was separately equilibrated to 37°C for 15 min. Following precomplexing of IgG with bead-captured virus, warmed NHS was directly added to the antibody-virus solution to achieve a ﬁnal serum dilution of 1:20 and incubated for 1 h at 37°C with gentle shaking. To measure baseline complement activation, bead-captured virus was incubated with NHS in the absence of
antibody. Excess antibody and serum were removed by two washes with PBS-BSA.
For the detection of C1q binding, serum-incubated bead-captured virus was incubated with mouse
anti-human C1q (clone JL-1, catalog number HM2382; Hycult Biotech) at 3 m g/ml for 30 min on ice, followed by two PBS-BSA washes. Secondary staining was performed using anti-mouse IgG-Alexa Fluor
647 (AF647) (catalog number A-21235; Invitrogen) diluted to 1:1,000 in PBS-BSA. Complement activation
was assessed by the detection of C3 deposition and C5b-9 formation. To measure the degree to which
test antibodies mediated C3 deposition, serum-incubated bead-captured virus was incubated with ﬂuorescein isothiocyanate (FITC)-conjugated anti-human C3 (catalog number C7652F; Cedarlane Labs) at
1 m g/ml for 20 min on ice, washed twice with PBS-BSA, and measured by ﬂow cytometry as described
below. To measure C5b-9 deposition, serum-incubated bead-captured virus was incubated with mouse
anti-SC5b-9/terminal complement complex (TCC)/neoantigen (catalog number A239; Quidel) at 1 m g/
ml, followed by two PBS-BSA washes and secondary staining with 1:200-diluted goat anti-mouse IgGAF647 (catalog number A-21235; Invitrogen), and for the detection of antibody binding, 1 m g/ml PE-conjugated goat anti-human IgG (catalog number 2040-09; Southern Biotech) was used. Beads were washed
out of the detection reagent and resuspended in PBS-BSA for ﬂow cytometric analysis on a MACSQuant
Analyzer 10 system (Miltenyi Biotec). Bead populations were ﬁrst gated for singlets before determining
the mean ﬂuorescence intensity (mFI). Data are reported as means and standard deviations from three
technical replicates and are representative of results from at least two independent experiments.
Antibody-dependent complement-mediated virolysis assay. Complement lysis of HIV-1 virions
was assessed by measurement of capsid protein p24, released following viral membrane disruption. In
96-well polystyrene tissue culture-treated microplates (catalog number 6916A05; Corning), 0.38 ng p24
of AT-2 HIV-1BaL and a 1:50 dilution of human complement serum (catalog number S1764; SigmaAldrich) were mixed with IgG in GVB11 for a total volume of 150 m l. To generate a p24 standard curve,
disruption buffer (catalog number 5421; ABL, Inc.) was added at a 1:10 dilution to serially diluted virions.
Heat-inactivated complement serum (56°C for 30 min) and wells containing active complement serum
without antibody served as negative controls for baseline p24 concentrations and complement-mediated lysis via antibody-independent pathways, respectively. Plates were incubated at 37°C for 1.5 h with
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gentle shaking before transferring 80 m l to black 96-well clear ﬂat-bottom plates (catalog number
655906; Greiner Bio-One). Each sample was assayed in triplicate.
Quantiﬁcation of released p24 was carried out using a bead-based sandwich assay. Brieﬂy, MagPlex
beads conjugated with two monoclonal murine anti-p24 antibodies (catalog numbers ab9072 and
ab9044; Abcam) were incubated with each sample for 1 h at RT with gentle orbital shaking (600 rpm),
followed by ﬁve washes on an automated plate washer. p24-bound beads were detected via 0.5 m g/ml
polyclonal rabbit anti-p24 antibodies (catalog number NBP2-41214; Novus Biologicals) for 1 h at room
temperature with shaking, washed ﬁve times, and stained with 0.6 m g/ml R-PE-conjugated rat anti-rabbit
Ig (catalog number 4065-09; Southern Biotech). After incubation and washing steps, beads were resuspended in xMAP sheath ﬂuid (Luminex Corp.), and MFI values were recorded by the Magpix system
(Luminex Corp.). Data are reported as means and standard deviations from three technical replicates
and are representative of results from at least two independent experiments.
C1q binding, C3 deposition, and SC5b-9 formation on cell surface-expressed gp140. FreeStyle
HEK293F cells (catalog number R79007; Thermo Fisher Scientiﬁc) were transiently transfected with a
plasmid encoding HIV-1JR-FL gp140 C-terminally linked to a GPI anchor using PEI (Polysciences). After
48 h, cells were washed out of culture media, and 1  105 live cells were transferred to each well of a
96-well cell culture plate. Fivefold serially diluted IgG (0.8 to 100 nM) was mixed with NHS or HI-NHS
diluted in GVB11 (for a ﬁnal dilution of 1:20) and incubated with gp140-expressing cells for 1.5 h at 37°C
with gentle shaking. Following incubation and prior to detection of C1q recruitment and two signatures
of complement activation, samples were transferred to 96-well V-bottom plates and washed three times
with cold PBS-BSA.
For the detection of C1q binding, cells were incubated with mouse anti-C1q (clone JL-1, catalog
number HM2382; Hycult Biotech) at 5 m g/ml and washed, and secondary staining was performed with
1:1,000-diluted anti-mouse IgG-Alexa Fluor 647 (catalog number A-21235; Invitrogen). To measure levels
of C3 deposition, cells were stained with a secondary detection solution consisting of 1 m g/ml FITC-conjugated mouse anti-human C3 (catalog number CL7632F; Cedarlane Lab), 1 m g/ml PE-conjugated goat
anti-human IgG (catalog number 2040-09; Southern Biotech), and 2 m g/ml propidium iodide (catalog
number P1304MP; Thermo Fisher) for 30 min on ice. For C5b-9 formation, mouse anti-SC5b-9 (catalog
number A239; Quidel) was incubated at 1 m g/ml, followed by two washes and secondary staining with
1:200-diluted goat anti-mouse IgG-AF647 (catalog number A-21235; Invitrogen), 1 m g/ml PE-conjugated
goat anti-human IgG (catalog number 2040-09; Southern Biotech), and 2 m g/ml propidium iodide.
Cells were washed out of the detection reagent and resuspended in PBS-BSA for ﬂow cytometric
analysis on a MACSQuant Analyzer 10 system (Miltenyi Biotec). The degrees of C1q binding, C3 deposition, and C5b-9 formation are shown as mean ﬂuorescence intensities of the singlet population gated
on live gp140-expressing cells. Baseline antibody-independent levels of C1q, C3 deposition, and C5b-9
formation were measured by incubating cells with NHS in the absence of antibody. Data are reported as
means and standard deviations from three technical replicates and are representative of results from at
least two independent experiments.
Transiently expressed HIV-1JR-FL gp140 HEK complement-dependent cytotoxicity assay. FreeStyle
HEK293F cells were transiently transfected to express HIV-1JR-FL gp140 as described above. In 96-well Ubottom tissue culture plates, antibodies and NHS were added to 2  105 live cells per well to achieve
ﬁnal concentrations of 20% (vol/vol) NHS and 100 nM IgG in GVB11. Negative-control wells without antibody were included to determine baseline antibody-independent complement activation. Plates were
incubated for 4 h at 37°C with orbital shaking before washing three times with PBS. Cells were stained
with the live/dead ﬁxable aqua dead cell marker (catalog number L34957; Life Technologies) diluted
1:250 in PBS and incubated for 30 min on ice. Wells were subsequently washed twice with PBS containing 1% BSA before resuspending the cells in PBS-BSA for analysis on the ﬂow cytometer. Percent lysis
was calculated as the number of cells staining strongly positive for the aqua dead cell marker divided by
the total number of cells processed. Data are reported as means and standard deviations from three
technical replicates and are representative of results from at least two independent experiments.
Env+ Raji cell complement-dependent cytotoxicity assay. Complement-dependent cytotoxicity
(CDC) of Raji cells transduced with a retroviral vector encoding HIV-1YU-2b Env was assessed as previously
described (22). Brieﬂy, transduced cells were generated by sorting for expression via a green ﬂuorescent
protein (GFP) reporter signal and clonally expanded to obtain cells expressing intermediate or high env
levels. Cells were mixed with 50% NHS or 50% heat-inactivated human serum and 10 m M IgG for 24 h at
37°C. Complement-mediated lysis was measured with the live/dead ﬁxable aqua dead cell marker (catalog number L34957; Life Technologies) prior to ﬁxation and ﬂow cytometric analysis (Attune NxT;
Invitrogen). CDC was reported as the relative percentage of dead cells compared to a “no-antibody” condition. Biological replicates consisted of three independent serum donors. Rituximab was used as a positive control for strong antibody-mediated CDC.
Data analysis. Structural images were rendered with PyMOL (Schrodinger). Graphical plots and analyses were performed in GraphPad Prism (version 9.0).
Data availability. The data sets generated and/or analyzed during the current study are available
from the corresponding author upon reasonable request.
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